

Provided by:



## Acute Leukemia and Myeloid Neoplasms Case Conference 2023-2024

**Acute Leukemia and Myeloid Neoplasms Case Conference 2023-2024 - 7/17/2024**

**July 17, 2024**

**12:00 PM - 1:00 PM**

**Perelman Center for Advanced Medicine, Conference Room 12-122**

### Target Audience

This program has been designed for INTERNAL MEDICINE - Hematology, INTERNAL MEDICINE - Medical Oncology, PATHOLOGY-ANATOMIC/PATHOLOGY-CLINICAL

### Series Educational Objectives

After participating in this regularly scheduled series, participants should be able to:

- 1 Discuss the importance of adequate marrow cellularity. Tracking technique of marrow. Involvement if pathology in educational series.
- 1 Describe and identify appropriate prophylactic therapies required for patients receiving therapy for acute leukemia.
- 2 Review the standard of care treatment, medications, concomitant medications, risks, benefits and potential toxicities or how to find out/whom to ask.

### Accreditation

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

### Designation of Credit

**Physicians:** Penn Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**ABIM MOC:** up to 1 MOC points

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

**ABPath MOC:** up to 1 MOC points

**Nurses:** This activity is for 1.00 contact hours.

**Pharmacists:** This activity is approved for 1.00 contact hours

UAN Number: JA0000324-0000-24-025-L04-P

For more information, please contact  
Tamieshia Nixon, Julie Mcdaniel, Michele Bloovman  
(215) 662-4074, (267) 970-8367, (215) 662-3191  
Tamieshia.Nixon@pennmedicine.upenn.edu, mcdjulie@upenn.edu,  
michele.bloovman@pennmedicine.upenn.edu

Check your transcript online at <https://upenn.cloud-cme.com>

**PAs:** Penn Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria.

This activity is designated for **1.00** AAPA Category 1 CME credit(s). PAs should only claim credit commensurate with the extent of their participation.

**Approved for (PSRM) patient safety/risk management designation**

**Acknowledgement of Commercial Support\***

None

### Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships(RFRs) that they have with any ineligible company, which is defined as any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Disclosure to learners includes all RFRs for all those in control of content including faculty, planners, moderators, and reviewers.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are evidence-based, are based on valid content, and are independent of control from ineligible companies and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain any financial relationships. Part of the peer review process involved reviewing the content, determining which financial relationships were relevant, and applying appropriate mitigation strategies. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no financial relationships with any ineligible companies. Any peer reviewer who is determined to have a relevant financial relationship must recuse themselves from the peer review process.

| Name of individual   | Individual's role in activity   | Nature of Relationship(s) / Name of Ineligible Company(s)  |
|----------------------|---------------------------------|--|
| Alison W Loren, MD   | Other Planning Committee Member | Nothing to disclose - 05/15/2024   |
| Alexander E Perl, MD | Other Planning Committee Member | Consulting Fee-AbbVie, Inc.   Advisor-Schrodinger (Relationship has ended)   Advisor-Aptose (Relationship has ended)   Advisor-Curis (Relationship has ended)   Advisor-Rigel (Relationship has ended)   Advisor-Immunogen (Relationship has ended)   Advisor-Actinium (Relationship has ended)   Consulting Fee-Astellas   Consulting Fee-Foghorn   Advisor-Bristol-Myers Squibb (Relationship has ended)   Advisor-Genentech   Consulting Fee-Daiichi Sankyo   Advisor-Syndax (Relationship has ended)   Consulting Fee-Leukemia and Lymphoma Society/BeatAML LLC   Grant or research support-AbbVie, Inc.   Grant or research support-Astellas   Grant or research support-Daiichi Sankyo   Grant or research support-Syndax   Grant or research support-FujiFilm (Relationship has ended) - 01/30/2024 |
| Noelle V. Frey, MD   | Other Planning Committee Member | Consulting Fee-Kite Pharma (Relationship has ended)   Consulting Fee-Autolus (Relationship has ended)   Consulting Fee-Sana Biotechnology (Relationship has ended) - 01/09/2024  |

|                                |                                 |  |
|--------------------------------|---------------------------------|--|
| Selina Luger, MD               | Other Planning Committee Member | Consulting Fee-Novartis (Relationship has ended)  Membership on Advisory Committees or Review Panels, Board Membership, etc.-Marker  Membership on Advisory Committees or Review Panels, Board Membership, etc.-daichi sankyo (Relationship has ended)  Membership on Advisory Committees or Review Panels, Board Membership, etc.-astellas (Relationship has ended)  Consulting Fee-marker therapeutics (Relationship has ended) - 01/22/2024 |
| Heather Difilippo, CRNP RN     | Other Planning Committee Member | Nothing to disclose - 05/21/2024   |
| Jacqueline Smith, CRNP         | Other Planning Committee Member | Nothing to disclose - 05/29/2024   |
| Elizabeth Hexner, MD           | Other Planning Committee Member | Grant or research support-Tmunity Therapeutics  Advisor-AbbVie, Inc.   Membership on Advisory Committees or Review Panels, Board Membership, etc.- Blueprint Medicines  Membership on Advisory Committees or Review Panels, Board Membership, etc.-Pharmessentia (Relationship has ended)  Membership on Advisory Committees or Review Panels, Board Membership, etc.-American Board of Internal Medicine - 05/23/2024                         |
| Maryellen Martin, MD           | Other Planning Committee Member | Nothing to disclose - 06/05/2024   |
| Linda Perry, PA-C              | Other Planning Committee Member | Paid consultant-Kadmon   Speakers Bureau-Sanofi Genzyme  Paid consultant-Incyte Corporation  Speakers Bureau-Incyte Corporation - 06/12/2024   |
| Kimberly A Hummel, BSN, RN     | Other Planning Committee Member | Nothing to disclose - 02/08/2024   |
| Shannon R. Mccurdy, MD         | Other Planning Committee Member | Nothing to disclose - 12/18/2023   |
| Jennifer J.D. Morrissette, PhD | Other Planning Committee Member | Honoraria-Novartis (Advanced Health Media) (Relationship has ended)  Advisor-AbbVie, Inc. (Relationship has ended)  Honoraria-Bayer (Relationship has ended)  Stocks or stock options, excluding diversified mutual funds of a publicly traded company- ThermoFisher - 01/30/2024  |
| Adam Bagg, MD                  | Co-Director, Faculty            | Nothing to disclose - 06/11/2024   |
| Martin Carroll, MD             | Other Planning Committee Member | Consulting Fee-Janssen Pharmaceuticals (J&J) (Relationship has ended)  Paid consultant-Cartography (Relationship has ended) - 06/13/2024   |
| Saar Gill, MD                  | Other Planning Committee Member | Consulting Fee-Hemogenyx (Relationship has ended)  Grant or research support- Interius  Grant or research support-Carisma (Relationship has ended) - 05/08/2024  |
| Colleen R Kucharzuk, CRNP RN   | Nurse Planner                   | Nothing to disclose - 05/08/2024   |

|                         |                                 |  |
|-------------------------|---------------------------------|--|
| Alison Carulli, PharmD  | Pharmacy Planner                | Nothing to disclose - 05/22/2024   |
| Keith Pratz, MD         | Course Director                 | Advisor-AbbVie, Inc.   Advisor-Bristol-Myers Squibb (Relationship has ended)   Advisor-Novartis / Amgen (Relationship has ended)   Advisor-Jazz Pharmaceuticals (Relationship has ended)   Advisor-Astellas (Relationship has ended)   Advisor-Astra Zeneca Pharmaceuticals (Relationship has ended)   Advisor-Roche (Relationship has ended) - 05/22/2024   |
| Andrew H Matthews, MD   | Other Planning Committee Member | Nothing to disclose - 12/11/2023   |
| Matthew Connor, MD      | Other Planning Committee Member | Nothing to disclose - 04/01/2024   |
| Ximena Jordan Bruno, MD | Other Planning Committee Member | Nothing to disclose - 01/23/2024   |
| Catherine Lai, MD, MPH  | Other Planning Committee Member | Advisor-Genentech   Advisor-Rigel   Advisor-Taiho Oncology (Relationship has ended)   Advisor-AbbVie, Inc.   Advisor-Novartis (Relationship has ended)   Consulting Fee-Jazz Pharma (Relationship has ended)   Advisor-Pfizer, Inc. (Relationship has ended)   Consulting Fee-PDS Biotechnology   Consulting Fee-Macrogenics (Relationship has ended)   Consulting Fee-Astellas (Relationship has ended)   Speakers Bureau-Jazz Pharma (Relationship has ended)   Speakers Bureau-Astellas (Relationship has ended)   Honoraria-OncoLive (Relationship has ended)   Honoraria-BioAscent (Relationship has ended)   Advisor-Daiichi (Relationship has ended) - 03/04/2024 |
| Sriram Anbil, MD        | Other Planning Committee Member | Nothing to disclose - 08/30/2023   |
| Minh Than, MD, PhD      | Other Planning Committee Member | Nothing to disclose - 05/21/2024   |
| Putzer Hung, MD, PhD    | Other Planning Committee Member | Nothing to disclose - 05/22/2024   |
| Shannon Ugarte          | Other Planning Committee Member | Nothing to disclose - 04/30/2024   |
| Eleanor P Taranto, MD   | Other Planning Committee Member | Nothing to disclose - 08/30/2023   |
| Jacob B Reibel, MD      | Other Planning Committee Member | Nothing to disclose - 08/08/2023   |

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected